Concept
Oncology Outcomes
Oncology outcomes research tracks survival, treatment effects, and care quality for people with cancer.
Students meet cancer epidemiology and outcomes early; this cluster keeps claims tied to measured endpoints.
Evidence
What the evidence shows
Drawn from 4 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
Multiple studies in this library examine oncology outcomes with empirical patient or population outcomes rather than opinion alone.
- ANXA1 in breast cancer prognosis
- Does socioeconomic status change cancer survival?
- Propofol vs sevoflurane and breast cancer survival
Study Role Design N Population Outcome ANXA1 in breast cancer prognosis Supports CohortPooled BCAC tumour series plus familial BRCA cases; ANXA1 IHC associations N=5752 · BCAC patients in primary analyses; plus familial BRCA cases in secondary analyses Women with breast cancer in pooled BCAC cohorts (mostly non-BRCA carriers) ANXA1 associations with tumour subtype markers and breast-cancer-specific survival Does socioeconomic status change cancer survival? Supports CohortNOWAC; education and household income vs cancer survival with stage and smoking adjustment N=3849 · 3,849 incident invasive cancers with SES data from a 91,814-woman study population Norwegian women with incident primary invasive cancer in NOWAC Cancer survival by education and household income Propofol vs sevoflurane and breast cancer survival Supports RCT1:1 propofol vs sevoflurane for anaesthesia maintenance in curative primary breast cancer surgery N=1670 · ITT: 841 propofol, 829 sevoflurane Patients undergoing curative primary breast cancer surgery 5-year overall survival High-grade tumors had higher ANXA1 odds (OR adj 1.59); ANXA1 linked to basal-like/TN features; HER2+ ANXA1-overexpressing cases had worse 10-year BCSS (HR adj 1.70).
An overall negative SES–survival gradient was present. Stage contribution was inconsistent, smoking was important, and after adjusting for stage and smoking the education and income differences became non-significant.
Among 1670 patients analysed by intention to treat (841 propofol, 829 sevoflurane), five-year survival was about 92% in both arms, with a hazard ratio near 1 and no statistically significant difference. Results were similar after per-protocol analysis and adjustment for uneven triple-negative receptor status.
All unmarried groups had excess mortality vs married; for men, never-married excess mortality rose ~3.4 percentage points per decade, mainly among those diagnosed after age 70.
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
Effect sizes and settings differ across oncology outcomes studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
- ANXA1 in breast cancer prognosis
- Does socioeconomic status change cancer survival?
- Propofol vs sevoflurane and breast cancer survival
Study Role Design N Population Outcome ANXA1 in breast cancer prognosis Supports CohortPooled BCAC tumour series plus familial BRCA cases; ANXA1 IHC associations N=5752 · BCAC patients in primary analyses; plus familial BRCA cases in secondary analyses Women with breast cancer in pooled BCAC cohorts (mostly non-BRCA carriers) ANXA1 associations with tumour subtype markers and breast-cancer-specific survival Does socioeconomic status change cancer survival? Supports CohortNOWAC; education and household income vs cancer survival with stage and smoking adjustment N=3849 · 3,849 incident invasive cancers with SES data from a 91,814-woman study population Norwegian women with incident primary invasive cancer in NOWAC Cancer survival by education and household income Propofol vs sevoflurane and breast cancer survival Supports RCT1:1 propofol vs sevoflurane for anaesthesia maintenance in curative primary breast cancer surgery N=1670 · ITT: 841 propofol, 829 sevoflurane Patients undergoing curative primary breast cancer surgery 5-year overall survival
Common misconceptions
Oncology Outcomes findings always generalise to every clinic.
These studies are context-bound; designs, populations, and endpoints limit transfer.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
What is Oncology Outcomes and why do health students study it?
Oncology outcomes research tracks survival, treatment effects, and care quality for people with cancer. Students meet cancer epidemiology and outcomes early; this cluster keeps claims tied to measured endpoints.
Name one limit of the evidence base for Oncology Outcomes in this library.
Single-setting trials, observational designs, or digital-only samples limit causal and external claims.
The studies
4 studies in this library bear on Oncology Outcomes, ordered by citations.
- Marital status and cancer survival trends
Among Norwegian cancer patients, never-married people—especially older men—showed growing excess mortality versus married peers over decades.
- ANXA1 in breast cancer prognosis
ANXA1-positive breast tumors clustered with poor-prognosis features (high grade, basal/TN, BRCA1/2) and worse outcomes in some high-risk subgroups such as HER2+.
- Does socioeconomic status change cancer survival?
In Norwegian women, lower education and income predicted worse cancer survival until stage and smoking were accounted for.
- Propofol vs sevoflurane and breast cancer survival
In the CAN randomised trial, five-year overall survival after primary breast cancer surgery was essentially the same with propofol or sevoflurane maintenance anaesthesia.
Learn alongside
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Rewordings are not listed.
- Concept page published